Comments
Loading...
Checkpoint Therapeutics Analyst Ratings and Price Targets | NASDAQ:CKPT | Benzinga
Checkpoint Therapeutics Inc has a consensus price target of $21 based on the ratings of 7 analysts. The high is $69 issued by Ladenburg Thalmann on April 3, 2023. The low is $4 issued by B. Riley Securities on December 20, 2023. The 3 most-recent analyst ratings were released by D. Boral Capital, HC Wainwright & Co., and Lake Street on March 31, 2025, March 11, 2025, and March 10, 2025, respectively. With an average price target of $4.33 between D. Boral Capital, HC Wainwright & Co., and Lake Street, there's an implied 8.20% upside for Checkpoint Therapeutics Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
D. Boral Capital
HC Wainwright & Co.
Lake Street
B. Riley Securities
Cantor Fitzgerald
1calculated from analyst ratings
Analyst Ratings for Checkpoint Therapeutics
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 03/31/2025 | Buy Now | 19.85% | D. Boral Capital | Jason Kolbert39% | $4.8 → $4.8 | Maintains | Buy | Get Alert |
| 03/11/2025 | Buy Now | 2.37% | HC Wainwright & Co. | Joseph Pantginis43% | → $4.1 | Downgrade | Buy → Neutral | Get Alert |
| 03/10/2025 | Buy Now | 2.37% | Lake Street | Thomas Flaten36% | $7 → $4.1 | Downgrade | Buy → Hold | Get Alert |
| 03/10/2025 | Buy Now | 19.85% | D. Boral Capital | Jason Kolbert39% | $9 → $4.8 | Maintains | Buy | Get Alert |
| 01/13/2025 | Buy Now | 124.72% | D. Boral Capital | Jason Kolbert39% | → $9 | Initiates | → Buy | Get Alert |
| 12/16/2024 | Buy Now | 74.78% | Lake Street | Thomas Flaten36% | $4 → $7 | Maintains | Buy | Get Alert |
| 12/16/2024 | Buy Now | 399.38% | HC Wainwright & Co. | Joseph Pantginis43% | $20 → $20 | Reiterates | Buy → Buy | Get Alert |
| 12/04/2024 | Buy Now | 399.38% | HC Wainwright & Co. | Joseph Pantginis43% | $20 → $20 | Reiterates | Buy → Buy | Get Alert |
| 11/14/2024 | Buy Now | 399.38% | HC Wainwright & Co. | Joseph Pantginis43% | $20 → $20 | Reiterates | Buy → Buy | Get Alert |
| 09/16/2024 | Buy Now | 399.38% | HC Wainwright & Co. | Joseph Pantginis43% | $20 → $20 | Reiterates | Buy → Buy | Get Alert |
| 08/12/2024 | Buy Now | 399.38% | HC Wainwright & Co. | Joseph Pantginis43% | $34 → $20 | Maintains | Buy | Get Alert |
| 07/16/2024 | Buy Now | 748.94% | HC Wainwright & Co. | Joseph Pantginis43% | $34 → $34 | Reiterates | Buy → Buy | Get Alert |
| 06/24/2024 | Buy Now | 748.94% | HC Wainwright & Co. | Joseph Pantginis43% | $34 → $34 | Reiterates | Buy → Buy | Get Alert |
| 05/16/2024 | Buy Now | 748.94% | HC Wainwright & Co. | Joseph Pantginis43% | $34 → $34 | Reiterates | Buy → Buy | Get Alert |
| 03/22/2024 | Buy Now | 748.94% | HC Wainwright & Co. | Joseph Pantginis43% | $34 → $34 | Reiterates | Buy → Buy | Get Alert |
| 12/20/2023 | Buy Now | -0.12% | B. Riley Securities | Mayank Mamtani70% | $8 → $4 | Maintains | Buy | Get Alert |
| 12/19/2023 | Buy Now | 748.94% | HC Wainwright & Co. | Joseph Pantginis43% | $34 → $34 | Reiterates | Buy → Buy | Get Alert |
| 08/16/2023 | Buy Now | 249.56% | Lake Street | Thomas Flaten36% | $16 → $14 | Maintains | Buy | Get Alert |
| 08/15/2023 | Buy Now | 249.56% | Cantor Fitzgerald | Jennifer Kim44% | $19 → $14 | Maintains | Overweight | Get Alert |
| 08/15/2023 | Buy Now | 1073.53% | Ladenburg Thalmann | Jeffrey Cohen29% | $65 → $47 | Maintains | Buy | Get Alert |
| 08/04/2023 | Buy Now | 748.94% | HC Wainwright & Co. | Joseph Pantginis43% | → $34 | Reiterates | Buy → Buy | Get Alert |
| 05/30/2023 | Buy Now | 299.5% | Lake Street | Thomas Flaten36% | $22 → $16 | Maintains | Buy | Get Alert |
| 05/17/2023 | Buy Now | 1522.97% | Ladenburg Thalmann | Jeffrey Cohen29% | $69 → $65 | Maintains | Buy | Get Alert |
| 05/16/2023 | Buy Now | 374.41% | Cantor Fitzgerald | Jennifer Kim44% | $54 → $19 | Maintains | Overweight | Get Alert |
| 04/28/2023 | Buy Now | 748.94% | HC Wainwright & Co. | Joseph Pantginis43% | $76 → $34 | Maintains | Buy | Get Alert |
| 04/04/2023 | Buy Now | 449.31% | Lake Street | Thomas Flaten36% | $32 → $22 | Maintains | Buy | Get Alert |
| 04/03/2023 | Buy Now | 1622.85% | Ladenburg Thalmann | — | $96 → $69 | Maintains | Buy | Get Alert |
| 03/02/2023 | Buy Now | 1797.63% | HC Wainwright & Co. | Joseph Pantginis43% | → $76 | Reiterates | → Buy | Get Alert |
| 01/04/2023 | Buy Now | 274.53% | Cantor Fitzgerald | Jennifer Kim44% | → $15 | Maintains | Overweight | Get Alert |
| 12/23/2022 | Buy Now | 1797.63% | HC Wainwright & Co. | Joseph Pantginis43% | $26 → $76 | Maintains | Buy | Get Alert |
| 12/19/2022 | Buy Now | 274.53% | B. Riley Securities | Mayank Mamtani70% | $7 → $15 | Maintains | Buy | Get Alert |
FAQ
What is the target price for Checkpoint Therapeutics (CKPT) stock?
The latest price target for Checkpoint Therapeutics (NASDAQ:CKPT) was reported by D. Boral Capital on March 31, 2025. The analyst firm set a price target for $4.80 expecting CKPT to rise to within 12 months (a possible 19.85% upside). 14 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Checkpoint Therapeutics (CKPT)?
The latest analyst rating for Checkpoint Therapeutics (NASDAQ:CKPT) was provided by D. Boral Capital, and Checkpoint Therapeutics maintained their buy rating.
When was the last upgrade for Checkpoint Therapeutics (CKPT)?
There is no last upgrade for Checkpoint Therapeutics
When was the last downgrade for Checkpoint Therapeutics (CKPT)?
The last downgrade for Checkpoint Therapeutics Inc happened on March 11, 2025 when HC Wainwright & Co. changed their price target from N/A to $4.1 for Checkpoint Therapeutics Inc.
When is the next analyst rating going to be posted or updated for Checkpoint Therapeutics (CKPT)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Checkpoint Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Checkpoint Therapeutics was filed on March 31, 2025 so you should expect the next rating to be made available sometime around March 31, 2026.
Is the Analyst Rating Checkpoint Therapeutics (CKPT) correct?
While ratings are subjective and will change, the latest Checkpoint Therapeutics (CKPT) rating was a maintained with a price target of $4.80 to $4.80. The current price Checkpoint Therapeutics (CKPT) is trading at is $4.01, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.